Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

When appearances are misleading: About one case of primary central nervous system lymphoma (PCNSL).

Harlay V, Boissonneau S, Chinot O.

Rev Neurol (Paris). 2019 Jun 21. pii: S0035-3787(18)30671-4. doi: 10.1016/j.neurol.2018.10.012. [Epub ahead of print] No abstract available.

PMID:
31235267
2.

The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials.

Coomans M, Dirven L, K Aaronson N, Baumert BG, van den Bent M, Bottomley A, Brandes AA, Chinot O, Coens C, Gorlia T, Herrlinger U, Keime-Guibert F, Malmström A, Martinelli F, Stupp R, Talacchi A, Weller M, Wick W, Reijneveld JC, Taphoorn MJB; EORTC Quality of Life Group and the EORTC Brain Tumor Group.

Eur J Cancer. 2019 Jul;116:190-198. doi: 10.1016/j.ejca.2019.05.012. Epub 2019 Jun 13.

PMID:
31203194
3.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network.

Neuro Oncol. 2019 May 17. pii: noz088. doi: 10.1093/neuonc/noz088. [Epub ahead of print]

PMID:
31102405
4.

Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.

Seliger C, Genbrugge E, Gorlia T, Chinot O, Stupp R, Nabors B, Weller M, Hau P; EORTC Brain Tumor Group.

Int J Cancer. 2019 Apr 13. doi: 10.1002/ijc.32337. [Epub ahead of print]

PMID:
30980539
5.

Correction to: Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.

Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D.

J Neurooncol. 2019 May;142(3):521. doi: 10.1007/s11060-019-03141-y.

PMID:
30859482
6.

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O, Moluçon-Chabrot C, Soubeyran P, Gressin R, Choquet S, Damaj G, Thyss A, Abraham J, Delwail V, Gyan E, Sanhes L, Cornillon J, Garidi R, Delmer A, Tanguy ML, Al Jijakli A, Morel P, Bourquard P, Moles MP, Chauchet A, Gastinne T, Constans JM, Langer A, Martin A, Moisson P, Lacomblez L, Martin-Duverneuil N, Delgadillo D, Turbiez I, Feuvret L, Cassoux N, Touitou V, Ricard D, Hoang-Xuan K, Soussain C; Intergroupe GOELAMS–ANOCEF and the LOC Network for CNS Lymphoma.

J Clin Oncol. 2019 Apr 1;37(10):823-833. doi: 10.1200/JCO.18.00306. Epub 2019 Feb 20.

PMID:
30785830
7.

Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.

Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D.

J Neurooncol. 2019 May;142(3):511-520. doi: 10.1007/s11060-019-03122-1. Epub 2019 Feb 11. Erratum in: J Neurooncol. 2019 Mar 11;:.

PMID:
30756272
8.

Angiotensin II receptor blockers, steroids and radiotherapy in glioblastoma-a randomised multicentre trial (ASTER trial). An ANOCEF study.

Ursu R, Thomas L, Psimaras D, Chinot O, Le Rhun E, Ricard D, Charissoux M, Cuzzubbo S, Sejalon F, Quillien V, Hoang-Xuan K, Ducray F, Portal JJ, Tibi A, Mandonnet E, Levy-Piedbois C, Vicaut E, Carpentier AF.

Eur J Cancer. 2019 Mar;109:129-136. doi: 10.1016/j.ejca.2018.12.025. Epub 2019 Feb 1.

PMID:
30716716
9.

Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.

Autran D, Barrie M, Matta M, Monserrat C, Campello C, Petrirena G, Boucard C, Padovani L, Loundou A, Appay R, Graillon T, Dufour H, Figarella-Branger D, Chinot O, Tabouret E.

Anticancer Res. 2019 Feb;39(2):1035-1041. doi: 10.21873/anticanres.13210.

PMID:
30711992
10.

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.

Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, Beauchesne P, Gressin R, Morschhauser F, Schmitt A, Gyan E, Hoang-Xuan K, Nicolas-Virelizier E, Cassoux N, Touitou V, Le Garff-Tavernier M, Savignoni A, Turbiez I, Soumelis V, Houillier C, Soussain C.

Ann Oncol. 2019 Apr 1;30(4):621-628. doi: 10.1093/annonc/mdz032.

PMID:
30698644
11.

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy.

Guedj E, Graillon T, Chinot O, Taieb D.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):537-538. doi: 10.1007/s00259-018-4221-y. Epub 2018 Dec 14. No abstract available.

PMID:
30552446
12.

(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.

Collignon A, Houillier C, Ahle G, Chinot O, Choquet S, Schmitt A, Agape P, Soussain C, Hoang-Xuan K, Tabouret E.

Ann Hematol. 2019 Apr;98(4):915-922. doi: 10.1007/s00277-018-3564-6. Epub 2018 Dec 7.

PMID:
30535802
13.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.

Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.

PMID:
30514777
14.

Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population.

Muracciole X, El-Amine W, Tabouret E, Boucekine M, Barlier A, Petrirena G, Harivony T, Solignac L, Chinot OL, Macagno N, Figarella-Branger D, Padovani L.

Front Oncol. 2018 Oct 4;8:426. doi: 10.3389/fonc.2018.00426. eCollection 2018.

15.

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J.

Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28.

PMID:
30266892
16.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
17.

Coping strategies and quality of life: a longitudinal study of high-grade glioma patient-caregiver dyads.

Baumstarck K, Chinot O, Tabouret E, Farina P, Barrié M, Campello C, Petrirena G, Hamidou Z, Auquier P.

Health Qual Life Outcomes. 2018 Aug 2;16(1):157. doi: 10.1186/s12955-018-0983-y.

18.

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M.

Eur J Cancer. 2018 Sep;101:95-104. doi: 10.1016/j.ejca.2018.06.029. Epub 2018 Jul 20.

PMID:
30036741
19.

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.

Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF.

Neuro Oncol. 2018 Oct 9;20(11):1525-1535. doi: 10.1093/neuonc/noy064.

20.

Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.

van Leeuwen M, Husson O, Alberti P, Arraras JI, Chinot OL, Costantini A, Darlington AS, Dirven L, Eichler M, Hammerlid EB, Holzner B, Johnson CD, Kontogianni M, Kjær TK, Morag O, Nolte S, Nordin A, Pace A, Pinto M, Polz K, Ramage J, Reijneveld JC, Serpentini S, Tomaszewski KA, Vassiliou V, Verdonck-de Leeuw IM, Vistad I, Young TE, Aaronson NK, van de Poll-Franse LV; EORTC QLG.

Health Qual Life Outcomes. 2018 Jun 4;16(1):114. doi: 10.1186/s12955-018-0920-0.

21.

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053.

22.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

Gao Y, Weenink B, van den Bent MJ, Erdem-Eraslan L, Kros JM, Sillevis Smitt P, Hoang-Xuan K, Brandes AA, Vos M, Dhermain F, Enting R, Ryan GF, Chinot O, Ben Hassel M, van Linde ME, Mason WP, Gijtenbeek JMM, Balana C, von Deimling A, Gorlia T, Stupp R, Hegi ME, Baumert BG, French PJ.

Eur J Cancer. 2018 May;94:168-178. doi: 10.1016/j.ejca.2018.02.023. Epub 2018 Mar 20.

PMID:
29571083
23.

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.

Petrirena GJ, Masliah-Planchon J, Sala Q, Pourroy B, Frappaz D, Tabouret E, Graillon T, Gentet JC, Delattre O, Chinot O, Padovani L.

Oncotarget. 2018 Jan 3;9(11):10175-10183. doi: 10.18632/oncotarget.23699. eCollection 2018 Feb 9.

24.

Differential scanning calorimetry of plasma in glioblastoma: toward a new prognostic / monitoring tool.

Tsvetkov PO, Tabouret E, Roman AY, Romain S, Bequet C, Ishimbaeva O, Honoré S, Figarella-Branger D, Chinot O, Devred F.

Oncotarget. 2018 Jan 25;9(10):9391-9399. doi: 10.18632/oncotarget.24317. eCollection 2018 Feb 6.

25.

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY.

Oncologist. 2018 May;23(5):524-e44. doi: 10.1634/theoncologist.2017-0689. Epub 2018 Feb 22.

26.

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.

Boisen MK, Holst CB, Consalvo N, Chinot OL, Johansen JS.

Oncotarget. 2017 Dec 4;9(6):6752-6762. doi: 10.18632/oncotarget.22886. eCollection 2018 Jan 23.

27.

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.

Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.

Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24.

28.

Clustering based on unsupervised binary trees to define subgroups of cancer patients according to symptom severity in cancer.

Michel P, Hamidou Z, Baumstarck K, Ghattas B, Resseguier N, Chinot O, Barlesi F, Salas S, Boyer L, Auquier P.

Qual Life Res. 2018 Feb;27(2):555-565. doi: 10.1007/s11136-017-1760-9. Epub 2017 Dec 8.

PMID:
29218507
29.

Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.

Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W.

Neuro Oncol. 2018 Mar 27;20(4):557-566. doi: 10.1093/neuonc/nox162.

30.

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro.

Graillon T, Romano D, Defilles C, Lisbonis C, Saveanu A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A.

Oncotarget. 2017 Jul 24;8(33):55361-55373. doi: 10.18632/oncotarget.19517. eCollection 2017 Aug 15.

31.

Dyadic effects of coping strategies, time perspectives, and personality on the quality of life of cancer patients and their caregivers.

Hamidou Z, Auquier P, Leroy T, Barlesi F, Salas S, Chinot O, Baumstarck K.

Psychooncology. 2018 Feb;27(2):590-599. doi: 10.1002/pon.4553. Epub 2017 Oct 6.

PMID:
28873265
32.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

33.

Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.

Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191.

34.

Evidence-based management of adult patients with diffuse glioma - Authors' reply.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Rhun EL, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Aug;18(8):e430-e431. doi: 10.1016/S1470-2045(17)30515-6. Epub 2017 Jul 26. No abstract available.

35.

[Adult intramedullary gliomas].

Campello C, Parker F, Slimani S, Le Floch A, Herbrecht A, Aghakhani N, Lacroix C, Loiseau H, Lejeune JP, Perrin G, Honnorat J, Dufour H, Chinot O, Figarella D, Bauchet L, Duffau H, Lonjon M, Labauge P, Messerer M, Daures JP, Fabbro P, Ducot B.

Neurochirurgie. 2017 Nov;63(5):381-390. doi: 10.1016/j.neuchi.2016.10.003. Epub 2017 May 18. French.

PMID:
28527519
36.

Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL.

Hamidou Z, Baumstarck K, Chinot O, Barlesi F, Salas S, Leroy T, Auquier P.

Health Qual Life Outcomes. 2017 May 12;15(1):99. doi: 10.1186/s12955-017-0672-2.

37.

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas.

Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Review. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

38.

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.

Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W.

Int J Mol Sci. 2017 May 6;18(5). pii: E995. doi: 10.3390/ijms18050995.

39.

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators.

N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi: 10.1056/NEJMoa1611977.

40.

IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas.

Verger A, Metellus P, Sala Q, Colin C, Bialecki E, Taieb D, Chinot O, Figarella-Branger D, Guedj E.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1306-1311. doi: 10.1007/s00259-017-3668-6. Epub 2017 Mar 14.

PMID:
28293705
41.

Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.

Farina P, Tabouret E, Lehmann P, Barrie M, Petrirena G, Campello C, Boucard C, Graillon T, Girard N, Chinot O.

J Neurooncol. 2017 May;132(3):433-437. doi: 10.1007/s11060-017-2385-0. Epub 2017 Mar 6.

PMID:
28265824
42.

Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study.

Ursu R, Carpentier A, Metellus P, Lubrano V, Laigle-Donadey F, Capelle L, Guyotat J, Langlois O, Bauchet L, Desseaux K, Tibi A, Chinot O, Lambert J, Carpentier AF.

Eur J Cancer. 2017 Mar;73:30-37. doi: 10.1016/j.ejca.2016.12.003. Epub 2017 Jan 28.

PMID:
28142059
43.

Patterns of response and relapse in primary CNS lymphomas after first-line chemotherapy: imaging analysis of the ANOCEF-GOELAMS prospective randomized trial.

Tabouret E, Houillier C, Martin-Duverneuil N, Blonski M, Soussain C, Ghesquières H, Houot R, Larrieu D, Soubeyran P, Gressin R, Gyan E, Chinot O, Taillandier L, Choquet S, Alentorn A, Leclercq D, Omuro A, Tanguy ML, Hoang-Xuan K.

Neuro Oncol. 2017 Mar 1;19(3):422-429. doi: 10.1093/neuonc/now238.

44.

Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.

Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A.

J Neurosurg. 2017 Sep;127(3):660-669. doi: 10.3171/2016.8.JNS16995. Epub 2016 Dec 16.

PMID:
27982767
45.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS.

J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5.

PMID:
27918718
46.

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Baumert BG, Hegi ME, van den Bent MJ, von Deimling A, Gorlia T, Hoang-Xuan K, Brandes AA, Kantor G, Taphoorn MJB, Hassel MB, Hartmann C, Ryan G, Capper D, Kros JM, Kurscheid S, Wick W, Enting R, Reni M, Thiessen B, Dhermain F, Bromberg JE, Feuvret L, Reijneveld JC, Chinot O, Gijtenbeek JMM, Rossiter JP, Dif N, Balana C, Bravo-Marques J, Clement PM, Marosi C, Tzuk-Shina T, Nordal RA, Rees J, Lacombe D, Mason WP, Stupp R.

Lancet Oncol. 2016 Nov;17(11):1521-1532. doi: 10.1016/S1470-2045(16)30313-8. Epub 2016 Sep 27.

47.

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Reijneveld JC, Taphoorn MJB, Coens C, Bromberg JEC, Mason WP, Hoang-Xuan K, Ryan G, Hassel MB, Enting RH, Brandes AA, Wick A, Chinot O, Reni M, Kantor G, Thiessen B, Klein M, Verger E, Borchers C, Hau P, Back M, Smits A, Golfinopoulos V, Gorlia T, Bottomley A, Stupp R, Baumert BG.

Lancet Oncol. 2016 Nov;17(11):1533-1542. doi: 10.1016/S1470-2045(16)30305-9. Epub 2016 Sep 27.

PMID:
27686943
48.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
49.

Changes in PlGF and MET-HGF expressions in paired initial and recurrent glioblastoma.

Tabouret E, Denicolai E, Delfino C, Graillon T, Boucard C, Nanni I, Padovani L, Figarella-Branger D, Chinot O.

J Neurooncol. 2016 Dec;130(3):431-437. Epub 2016 Aug 26.

PMID:
27566180
50.

Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.

Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D.

Oncotarget. 2016 Sep 20;7(38):61916-61929. doi: 10.18632/oncotarget.11322.

Supplemental Content

Loading ...
Support Center